-+ 0.00%
-+ 0.00%
-+ 0.00%

Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases

PUBT·09/14/2026 12:07:02
Listen to the news
Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases
  • Akebia Therapeutics dosed the first patient in an open-label Phase 2 basket trial of ebribafusp for rare kidney diseases.
  • Initial results have not been presented; first data are expected in 2027.
  • The study aims to show whether the drug can reduce kidney inflammation and protein leakage while maintaining broader immune defenses.
  • Up to 30 patients are planned, positioning the program for a clearer go/no-go decision on broader development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED9826135) on September 14, 2026, and is solely responsible for the information contained therein.